# A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

> **NCT06474663** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Refractory Acute Leukemia
- Relapsed Acute Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **DRUG:** Sorafenib
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT06474663
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07-31
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participants
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06474663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06474663, "A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06474663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*